Selected research
-
Development of a Safety Surveillance Plan for The Academic Medicine Sponsor Performing First in Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy.
Transplantation and cellular therapy
-
Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies.
Pediatric blood & cancer
-
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
Clinical trials
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
To measure the response of treatments chosen based on: • Event free survival (EFS)
Recruiting
More about this studyEflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
To evaluate the efficacy of difluoromethylornithine (DFMO) in combination with etoposide in patients with relapsed/refractory neuroblastoma, based upon: o Event free survival (EFS) from time of enrollment.
Recruiting
More about this studyNaxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Measured by the presence of radiologically assessable disease by cross-sectional computed tomography (CT) or Magnetic resonance imaging (MRI) imaging and/or by metaiodobenzylguanidine (MIBG) or positron emission tomography (PET) s...
Recruiting
More about this studyChemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusi...
The Kaplan-Meier method will be used to estimate 3-year FFS along with 80% log-minus-log transformed confidence limits for very low risk (VLR) patients.
Recruiting
More about this studyProject: Every Child for Younger Patients With Cancer
The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue saved for future research.
Recruiting
More about this studyInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL...
Improvement in 5-year disease-free survival (DFS) with modified Berlin-Frankfurt-Münster (mBFM) chemotherapy without delayed intensification (DI) part 2 but with inotuzumab ozogamicin, versus full mBFM chemotherapy backbone includ...
Recruiting
More about this studyA Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Dia...
Will be assessed in SR-High patients and SR-Avg B-ALL patients who are negative for MRD by flow cytometry but have detectable or indeterminate MRD as measured by high throughput sequencing (HTS) at end of induction (EOI), and pati...
Recruiting
More about this studyDFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
o To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in preventing relapse in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon the 2...
Recruiting
More about this studyA Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute ...
Summary statistics will be used to characterize the study populations on CHC outcomes. Quantitative data (number of comorbidities) will be summarized using descriptive statistics and correlational techniques. Will use pooled logis...
Recruiting
More about this studyContact me
Where I see patients (5)
Smell the roses